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One example of this approach would be to consider the 
major risk factors for sporadic Alzheimer’s disease viz: age 
and possession of the ε4 allele of apolipoprotein e (APOE4), 
and take the lead from observations in human brains to ask 
the questions “Why does Aβ accumulate in the brain with 
age?” “What are the pathophysiological consequences for the 
brain of the accumulation of Aβ in the walls of cerebral arter-
ies and in brain parenchyma?” It is clear from the study of 
human brains that there is an age-related failure of elimina-
tion of Aβ. experimental studies and observations in human 
brains suggest that various pathways for the elimination of 
Aβ from the brain fail with age. Those pathways include deg-
radation by neprilysin [11] and other enzymes and absorp-
tion of Aβ into the blood [13, 19]. In addition, there is an 
age-related failure of elimination of Aβ along the perivascular 
drainage pathways [7] that serve as lymphatic drainage path-
ways for interstitial fluid and solutes (including Aβ) from the 
brain [4, 5, 17]. Impaired elimination of Aβ along perivascu-
lar drainage pathways is further accentuated in the presence 
of APOE4 [8]. Hallmarks of such failure are the deposition 
of Aβ aggregates in the walls of arteries as cerebral amyloid 
angiopathy (CAA) and as plaques of Aβ in the brain paren-
chyma; there is also a rise in the level of soluble Aβ in the 
brain in Alzheimer’s disease [9, 15] and the accumulation of 
fluid in subcortical white matter as leukoaraiosis [12]. The 
significance of CAA has been emphasised in human and 
experimental studies which showed that severe CAA was 
strongly related to the presence of dementia [6, 18].
Two major causes of age-related failure of perivascular 
elimination of Aβ from the brain have been identified, first: 
the progressive stiffening that occurs in the walls of cerebral 
arteries with age [16]; second: the changes that occur in 
basement membranes with age [7]. Theoretical models sug-
gest that the contrary wave that follows the pulse wave along 
cerebral arteries is a major motive force for perivascular 
In the October 2013 issue of Acta Neuropathologica there 
were three very interesting articles on: Amyloid or tau: the 
chicken or the egg? In the first article, David Mann and 
John Hardy [10] argued that the deposition of aggregated 
amyloid β (Aβ) protein in the brain is a primary driving 
force behind the pathogenesis of Alzheimer’s disease with 
tau pathology following as a consequential or at least a sec-
ondary event. In the communication that followed, Braak 
and Del Tredici [3] presented the contrary argument with 
accumulation of tau protein as the primary event in spo-
radic Alzheimer’s disease. Attems and Jellinger [2] ques-
tioned the concept of a chicken and egg and suggested that 
the majority of cases of age-associated dementia are not 
caused by one single primary pathological mechanism.
Many of the arguments put forward in these three contri-
butions rely on observations derived from human brain mate-
rial. Although human brain specimens have been essential 
for defining the diagnosis of Alzheimer’s disease and other 
dementias and for identifying some of the problems associ-
ated with those dementias, the study of human material is 
not necessarily the best and sole way of solving the “chicken 
and egg” problem. It is tacitly assumed that the primary prob-
lems lie with the deposition of insoluble Aβ as plaques in the 
brain, or the toxicity of soluble Aβ, or with the accumulation 
of hyperphosphorylated tau in neurons and neurites. But, have 
we identified the egg? What is the primary problem? In order 
to answer this question we should perhaps review the changes 
that occur in the brain with age and how they affect the patho-
physiology of the brain and result in dementia.
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drainage of Aβ from the brain [14]. According to this model, 
stiffening of cerebral arteries would reduce the amplitude of 
pulsations and thus reduce the motive force for drainage of 
Aβ. This is supported by experimental studies showing that 
a reduction in arterial pulsations impedes perivascular drain-
age [1]. Age-related changes in vascular basement mem-
branes that are the pathways for perivascular drainage and 
in their component proteins have been detected in human 
cerebral arteries (see [7]); in mice such changes are associ-
ated with demonstrably impaired perivascular drainage [7]. 
Impairment and slowing of perivascular drainage is associ-
ated with the formation of fibrillar amyloid in the walls of 
cerebral vessels as CAA which further impedes perivascular 
drainage of Aβ [7]. stiffening of cerebral artery walls and 
age-related changes in basement membranes appear to be 
universal factors in the failure of perivascular elimination of 
Aβ from the ageing brain and in Alzheimer’s disease.
What, therefore, is the egg? Age-changes in the walls 
of cerebral arteries that impair the drainage of soluble Aβ 
could well be a prime candidate [7]. The chicken that devel-
ops from this egg may be the accumulation of insoluble 
aggregates of Aβ as CAA and as plaques in the brain but 
it could also be loss of homoeostasis of the neuronal envi-
ronment due to failure of elimination of a range of soluble 
metabolites from the brain parenchyma.
We have emphasised here that, despite the importance of 
studying the distribution of Aβ and tau in human post-mor-
tem brain in dementias such as Alzheimer’s disease, it is 
equally important to consider the wider pathophysiological 
effects of ageing of cerebral arteries on the brain in relation 
to Alzheimer’s disease. such changes may lead not only 
to the accumulation of Aβ in the brain and artery walls but 
also to loss of homoeostasis of the neuronal environment 
and disturbance of neuronal function that may be related 
to dementia. Facilitation of elimination of soluble Aβ and 
other metabolites from the brain along the walls of ageing 
arteries could be a fruitful therapeutic strategy for the pre-
vention and management of Alzheimer’s disease [5].
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